Medical Device Network on MSN17d
FDA clears Tandem’s Control-IQ+ technology for type 2 diabetes
The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin delivery algorithm, for use in individuals aged 18 and above with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results